BDPT BioAdaptives Inc

BioAdaptives® Announces Commercial Launch of MyndMed™ Following Successful Pilot Testing

BioAdaptives® Announces Commercial Launch of MyndMed™ Following Successful Pilot Testing

Comprehensive cognitive-support formula now available online; company scaling production for anticipated Q4 demand

LAS VEGAS, Oct. 07, 2025 (GLOBE NEWSWIRE) -- via IBN -- (OTC: BDPT) today announced the commercial availability of MyndMed™, a next-generation cognitive-support dietary supplement formulated to support memory, focus, mental clarity, and overall brain performance. Following rigorous testing with overwhelmingly positive results, the company is expanding distribution and scaling inventory to meet the expected high order volumes from November onward.

"After extensive testing, we're thrilled to bring MyndMed™ to a wider audience," said James Keener, CEO of BioAdaptives Inc. "Users have reported enhanced focus, reduced brain fog, and sustained energy without the jitters of traditional stimulants. With our soft launch proving demand, we're gearing up for explosive growth this fall, making MyndMed™ accessible to anyone seeking a mental edge in work, sports, or daily life."

Why MyndMed™

MyndMed™ brings together well-studied nutrients to support key cognitive pathways, including cholinergic tone, neuronal energy metabolism, antioxidant defenses, and neuroplasticity. Together, these ingredients are intended to support:

  • Short-term: sustained alertness, calm focus, and memory support.
  • Mid-term: synaptic efficiency and cognitive processing speed support.
  • Long-term: cellular energy, antioxidant balance, and neuroprotective support.

“Our guiding principle with MyndMed™ was to create a first-in-class nootropic that delivers “Mental Armor for Modern Minds™” added James Keener, CEO. “The stack addresses complementary mechanisms—from acetylcholine dynamics to mitochondrial function and antioxidant status—while remaining compliant with World Anti-Doping Association (WADA) regulations.”

Quality & Compliance

  • Manufactured in the USA in cGMP-certified facilities.
  • Third-party tested for identity, purity, and heavy metals.
  • Transparent labeling with no proprietary blends.

Availability & Ordering

MyndMed™ is available now at . The product ships nationwide in the U.S. with standard and expedited options. For introductory promotions and subscription savings, visit the product page.

About BioAdaptives, Inc.

BioAdaptives, Inc. develops and markets science-based natural health and wellness products for both humans and animals. Its formulations leverage cutting-edge research in stem cell biology, adaptogens, and regenerative nutrition. The company’s mission is to enhance the quality of life through innovation that works in harmony with the body’s natural processes.

For more information, visit: .

Contact:

Emily Harrison

Investor Relations

BioAdaptives, Inc.

(702) 659-8829

 



EN
07/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioAdaptives Inc

 PRESS RELEASE

BioAdaptives® Announces Commercial Launch of MyndMed™ Following Succes...

BioAdaptives® Announces Commercial Launch of MyndMed™ Following Successful Pilot Testing Comprehensive cognitive-support formula now available online; company scaling production for anticipated Q4 demand LAS VEGAS, Oct. 07, 2025 (GLOBE NEWSWIRE) -- via IBN -- (OTC: BDPT) today announced the commercial availability of MyndMed™, a next-generation cognitive-support dietary supplement formulated to support memory, focus, mental clarity, and overall brain performance. Following rigorous testing with overwhelmingly positive results, the company is expanding distribution and scaling inventory...

 PRESS RELEASE

BioAdaptives’ MyndMed™ Receives Full Clearance from TruShield™, Meetin...

BioAdaptives’ MyndMed™ Receives Full Clearance from TruShield™, Meeting UFC and WADA Standards for Athlete Safety Unique nootropic formula blends botanical extracts, amino acids and neuro-support nutrients to support balance, energy and resilience in athletes LAS VEGAS, Aug. 20, 2025 (GLOBE NEWSWIRE) -- via IBN – (OTCMKTS: BDPT), a leader in natural health and performance supplements, today announced that its flagship nootropic formula, MyndMed™, has been officially certified clean by TruShield™ Laboratory Services, a trusted provider of sports supplement testing specializing in World ...

 PRESS RELEASE

BioAdaptives Announces National Launch of NeuroRush™ — A Cutting-Edge ...

BioAdaptives Announces National Launch of NeuroRush™ — A Cutting-Edge Adaptogenic Nootropic for Mental Clarity, Focus, and Resilience NeuroRush™ delivers a unique blend of adaptogens and nootropic herbs designed to enhance cognitive performance, stress response and long-term brain health, without dependency or burnout. LAS VEGAS, July 16, 2025 (GLOBE NEWSWIRE) -- (OTC: BDPT), an innovator in evidence-based wellness solutions, today announced the upcoming national release of NeuroRush™, a next-generation nootropic designed to support sustained cognitive performance, mental clarity, and ...

 PRESS RELEASE

BioAdaptives Announces National Launch of Pawpa™ Regen

BioAdaptives Announces National Launch of Pawpa™ Regen Revolutionary Canine Supplement Promotes Regenerative Healing Through Stem Cell Activation LAS VEGAS , June 24, 2025 (GLOBE NEWSWIRE) -- via IBN -- (OTC Pink: BDPT), an innovator in nutraceutical and wellness science, today announces the upcoming national release of , a proprietary canine supplement that supports natural stem cell activation and regenerative healing in aging dogs. After a successful limited market release earlier this year, Pawpa™ Regen officially launches nationwide at the end of July 2025. This breakthrough form...

 PRESS RELEASE

BioAdaptives® PawPa™ Regen Provides Breakthrough Stem Cell Support for...

BioAdaptives® PawPa™ Regen Provides Breakthrough Stem Cell Support for Pets, Backed by Clinically Proven APBAR® Scale Improvements Regen Dog Chews are crafted to the highest quality standards, recommended by veterinarians and proven safe with no adverse effects reported in clinical trials LAS VEGAS, May 28, 2025 (GLOBE NEWSWIRE) -- via IBN -- . (OTC: BDPT), through its pets division PawPa™, a leader in premium pet wellness, proudly announces the remarkable stem cell benefits of its flagship product, Regen Dog Chews, validated through rigorous clinical testing and the innovative APBAR® r...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch